Please enable JavaScript or talk to your local administrator to get JavaScript enabled.


UROthelial carcinoma Biomarker based diagnostic tEST

Funder: European Commission

Funding period
EUR 50 K
USD 55 K
Funding amount
Bladder cancer is among the five most common malignancies worldwide: more than 380.000 new cases are diagnosed yearly. If detected early, 5-year survival is high (94%),but >70% of diagnosed patients will relapse within this period.
The current gold standard diagnostic tool is combined cytology and cystoscopy which is costly and highly invasive requiring transurethral access and presenting the risk of important complications. Due to high relapse rates, surveillance requires frequent cystoscopies, averaging 13 controls per patient after initial diagnosis. Hence, bladder cancer is one of the costliest cancers to treat and monitor. Only in the USA, Europe and Japan, more than 4.5 million cystoscopies are conducted yearly, 40% for 1st diagnosis and 60% for surveillance, at a cost near to $2 billion to healthcare providers.
Urologists believe that an opportunity exists to reduce the number of SURVEILLANCE cystoscopies with a reliable, cost-effective, robust, easy-to-perfom and non-invasive assay.
URO-BEST addresses this unmet need. Based on signatures of 2, 5,10 and 12 differentially-expressed genes, this test has been clinically validated in a multicenter international study on 525 urine samples demonstrating 81% sensitivity and 91% specificity in discriminating cases vs. healhty patients for first diagnosis, figures comparable to that of the gold standard and superior to other existing molecular diagnostic products (Urovysion, NMP22, BTA Stat). We estimate the current market for bladder cancer biomarker based tests at greater than > $200million.
Fina Biotech has filed European and PCT patent applications protecting the invention in 2013.
Fina Biotech aims to clinically validate the diagnostic performance of the genetic signatures in patients under SURVEILLANCE for its launch to the market: advance ongoing discussions with potential partners for global licensing,increase urologists awareness and secure freedom to operate.
Similar projects All >
Sorted by: Start Date
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

2019 - 2023
Project list item
Implementing Risk-aligned Bladder Cancer Surveillance

United States Department of Veterans Affairs to FLORIAN R SCHROECK

2019 - 2023
Project list item
Multi4 - a new surgical instrument for diagnosis and treatment of bladder cancer within cystoscopy

VINNOVA to Miden Melle-Hannah

USD 52,877
2019 - 2019
Project list item
Ultrasound-based diagnostic and monitoring of bladder cancer treatment with drug released from nanoparticles

National Cancer Institute to JOE ASSOULINE, YI LUO

USD 350,240
2018 - 2020
Project list item
Novel Biomarkers for the Clinical Management of Bladder Cancer

National Cancer Institute to VINATA B LOKESHWAR

USD 902,622
2018 - 2023



    1112 Oncology and Carcinogenesis

  • RCDC


  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases




    4.1 Discovery and preclinical testing of markers and technologies


    4.2 Evaluation of markers and technologies

  • Health Research Areas